13F Holdings
中文EN

LBRX LB PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1691082 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-650.9%
TTM EPS YoY94.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-38.8%
ROA-36.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets7.9%
Debt / equity0.00x
Current ratio14.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$51.52M$44.15M$14.64M$8.48M$2.42M$2.42M$3.42M$376,000
SG&A expense$10.98M$9.77M$7.46M$5.39M$2.83M$2.44M$3.01M$5.16M
Pretax income-$59.07M-$51.60M-$19.05M-$11.47M-$3.56M-$4.87M-$5.31M-$5.07M
Income tax$0$0$0$1,000$0$0$0$1,000
Net income-$59.07M-$51.60M-$19.05M-$11.47M-$3.56M-$4.87M-$5.31M-$5.07M
EPS (basic)-1.79-1.71-0.67—-0.61-13.58-14.79—
EPS (diluted)-1.79-1.71-0.67—-0.61-13.58-14.79—
Weighted avg. shares (diluted)33.08M30.14M28.24M—5.81M358,811358,777—
Balance sheet
Cash & equivalents$215.07M$283.11M$320.68M$250.17M$269.74M——$22.98M
Short-term investments$188.69M$44.68M$44.96M$45.04M$44.73M——$5.02M
Current assets$447.12M$355.30M$389.07M$308.43M$316.40M——$28.88M
PP&E, net$2.15M$2.20M$1.53M$1.58M$1.64M——$1.86M
Total assets$453.37M$361.69M$393.48M$312.93M$320.75M——$33.53M
Current liabilities$30.25M$23.56M$10.91M$7.44M$6.65M——$8.11M
Total liabilities$35.73M$29.34M$14.79M$11.62M$10.53M——$13.83M
Shareholders' equity$417.64M$332.35M$378.69M$301.31M$310.22M-$103.87M-$99.34M-$94.55M
Shares outstanding32.27M28.68M28.67M25.30M25.30M——251,655
Cash flow statement
Operating cash flow-$64.29M-$37.63M-$23.29M-$18.10M-$3.37M-$5.60M-$8.13M-$5.67M
Capital expenditure$70,000$363,000$32,000$40,000$0-$9,000$21,000$238,000
Free cash flow-$64.36M-$37.99M-$23.32M-$18.14M-$3.37M-$5.59M-$8.15M-$5.90M
Investing cash flow-$144.65M$89,000-$32,000-$40,000-$44.84M$9,000$4.98M$13.54M
Financing cash flow$140.92M-$19,000$93.83M-$1.17M$303.73M$0$0$0
Depreciation & amortization$124,000$97,000$82,000$85,000$81,000$76,000$79,000$80,000
Stock-based compensation$3.67M$4.90M$2.57M$2.34M$881,000$335,000$634,000$2.28M

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.